GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » Insider Ownership

IRWD (Ironwood Pharmaceuticals) Insider Ownership : 6.34 % (As of Dec. 14, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Ironwood Pharmaceuticals Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ironwood Pharmaceuticals's insider ownership is 6.34%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ironwood Pharmaceuticals's Institutional Ownership is 99.86%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ironwood Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 51.74%.

Ironwood Pharmaceuticals Insider Ownership Historical Data

The historical data trend for Ironwood Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals Insider Ownership Chart

Ironwood Pharmaceuticals Historical Data

The historical data trend for Ironwood Pharmaceuticals can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Insider Ownership 6.21 6.55 6.45 6.37 6.40 6.40 6.37 6.37 6.37 6.34

Ironwood Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Ironwood Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » Insider Ownership
Comparable Companies
SUPN PCRX TARO TLRY ANIP DCPH DVAX AVDL COLL AMRX ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Website
https://www.ironwoodpharma.com
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Executives
Andrew Davis officer: SVP, Chief Business Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sravan Kumar Emany officer: SVP, Chief Financial Officer 100 SUMMER ST, SUITE 2300, BOSTON MA 02109
Ronald Silver officer: Principal Accounting Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Minardo John officer: Chief Legal Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Catherine Moukheibir director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Michael Shetzline officer: CMO,SVP,Head-Res&Drug 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Thomas A Mccourt officer: Chief Commercial Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jon R Duane director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Marla L Kessler director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jason Rickard officer: SVP, Chief Operating Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark G Currie officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Gina Consylman officer: Chief Accounting Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110